Business Wire

WorldFirst’s 1688 Global Sourcing Integration Sees Adoption Surge as SME Buyers Seek Competitive Edges

8.9.2023 06:27:00 EEST | Business Wire | Press release

Share

WorldFirst, a one-stop global payment and financial services platform for SMEs engaged in cross-border trade, reported that international SME buyers have increasingly adopted the WorldFirst Cross-border Pay solution for 1688, one of China's top wholesale marketplaces, as SMEs worldwide seek cost-effective sourcing options to stay competitive.

During the first eight months of 2023, turnover generated by WorldFirst SME customers which sourced from 1688’s vast product marketplace through Cross-border Pay increased by over 50% to more than 22 billion yuan, or 3.03 billion US dollars. The number of new SMEs who signed up for the solution rose nearly 20%. Stationaries, petting products, gardening supplies, toys, and storage containers were among the most popular goods for these international buyers.

“We understand the immense potential that lies in helping SMEs to compete on a global scale," said Daniel Chua, Head of Commercial for Southeast Asia, WorldFirst. "By integrating with 1688, we aim to help businesses of all sizes to efficiently source products from one of the world's largest wholesale markets, regardless of their location. This integration underscores our commitment to helping SMEs thrive globally."

With the explosive growth of e-commerce, SMEs have increasingly turned to platforms like 1688 for diverse sourcing options. However, navigating the complexities of international payments and currency exchanges has historically posed challenges for these businesses. As an official payment partner with 1688, WorldFirst collaborated with the marketplace to jointly launch Cross-border Pay in 2019, aiming to address these pain points and streamline the way SMEs access and transact with suppliers on 1688.

WorldFirst Cross-border Pay offers international buyers an option to make payments to 1688 sellers without the need to set up an onshore bank account in China. The buyers will also benefit from highly competitive foreign exchange rates, as inbound payment is settled at the offshore yuan rate.

Cross-border Pay usage also increased in Southeast Asian markets where the solution is available. During the first eight months, Cross-border Pay turnover, or transaction volume, by buyers from Singapore, Malaysia and Thailand grew 21%, 11%, and 11%, respectively, from the same period a year earlier. The number of new Cross-border Pay customers from Singapore more than doubled and that from Malaysia surged 69% on year.

Since its launch in 2019, Cross-border Pay has experienced consistent year-on-year growth in annual turnover. “This shows a global payment solution designed to continuously assists SMEs in saving costs and time in international trade is a crucial need of businesses today. And we plan to roll out Cross-border Pay to more markets to help SMEs stay competitive, expand their product offerings, and ultimately drive growth,” said Chua.

Cross-border Pay is currently available primarily in Southeast Asia, Australia, and other Asia Pacific markets. WorldFirst, a member of Ant Group, plans to introduce the solution to the United Kingdom and continental European markets in the coming months.

With 19 years’ experience in facilitating cross-border payments, WorldFirst has consistently strived to offer ground-breaking solutions that help SMEs grow globally. At the 2023 INCLUSION·Conference on the Bund, held from Thursday to Saturday in Shanghai, China, WorldFirst unveiled a set of upgraded features. Notably, the latest enhancements will allow China-based sellers to effortlessly set up a store on over 30 overseas marketplaces through a single application.

Launched in 1999, 1688 is China’s largest integrated domestic wholesale marketplace in 2021 by net revenue, according to Analysys. It provides sourcing and online transaction services by connecting manufacturers and wholesale sellers to wholesale buyers in China. In recent years, 1688, a business of Alibaba Group, has attracted a growing number of cross-border buyers to access its vast array of products. According to 1688, there are 5.7 million cross-border buyers, contributing to a quarter of its annual GMV.

About WorldFirst

WorldFirst was founded in 2004 and joined Ant Group in 2019. Through the World Account, WorldFirst is meeting the needs of SMEs engaged in international trade or business, both online via marketplaces or websites, as well as offline to support importers and exporters. This includes global collection (receiving payments), making payments, currency conversion, risk management, and supply chain financing to help WorldFirst customers reduce costs, improve turnover efficiency to generate more revenue and sales, and quickly capture global business opportunities. WorldFirst serves one million customers worldwide and is connected to over 100 marketplaces. To learn more about WorldFirst at https://www.worldfirst.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Martin Mou
mou.xu@worldfirst.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye